Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ALDX
Strong SellSinkerAldeyra Therapeutics, Inc. · Healthcare · United States · $90M · Avg Vol: $1M/d
COMPANY DESCRIPTION
Aldeyra Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for immune-mediated diseases caused by inflammation and oxidative stress. It utilizes a proprietary RASP (reactive aldehyde species) modulator platform to target underlying disease mechanisms, with lead candidates in late-stage clinical trials for ocular and systemic inflammatory conditions. The company is a specialized biopharmaceutical firm focused on a distinct therapeutic approach, aiming to address significant unmet needs in inflammatory and autoimmune disorders.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | 1.7M | 6.7M | — |
| EPS | -1.06 | -0.64 | -0.94 | -0.56 | — | -0.38 | -0.34 | -0.28 | — |
| Shares | 58.6M | 59.2M | 59.6M | 60.2M | +2.7% | 60.3M | — | — | — |
| Debt | 16.1M | 15.7M | 15.3M | 15.5M | -1.2% | — | — | — | — |
| Equity | 151.0M | 119.8M | 71.0M | 44.3M | -33.6% | — | — | — | — |
| Op CF | -56.6M | -30.3M | -43.2M | -33.3M | — | -22.0M | — | — | — |
| Inv CF | -30.0M | 30.0M | -44.9M | 47.7M | — | — | — | — | — |
| Fin CF | 1.2M | -1.3M | -0.2M | 1.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ALDX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ALDX | Aldeyra Therapeutics, Inc.(you) | $90M | 4 | Strong Sell |
| GOSS | Gossamer Bio, Inc. | $83M | 2 | Strong Sell |
| PLYX | Polaryx Therapeutics, Inc. | $103M | 5 | Strong Sell |
| KLRS | Kalaris Therapeutics, Inc. | $96M | 7 | Strong Sell |
| NAUT | Nautilus Biotechnology, Inc. | $113M | 4 | Strong Sell |
| VRCA | Verrica Pharmaceuticals Inc. | $98M | 7 | Strong Sell |
| ONCY | Oncolytics Biotech Inc. | $109M | 5 | Strong Sell |
| CING | Cingulate Inc. | $77M | 6 | Strong Sell |
| DWTX | Dogwood Therapeutics, Inc. | $90M | 9 | Strong Sell |
| ELTX | Elicio Therapeutics, Inc. | $75M | 2 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%